Keyphrases
Peru
100%
Cost-effectiveness
100%
Carbapenem-resistant Bacteria
100%
Ceftazidime-avibactam
100%
Colistin
62%
Pneumonia
50%
Bacteremia
50%
Carbapenem-resistant Enterobacteria
50%
Peruvian
37%
Gross Domestic Product
25%
Dialysis
25%
Long-term Care
25%
Health Status
12%
Incremental Cost
12%
Model Simulation
12%
Hospital Days
12%
S-23
12%
Home Care
12%
Therapy Approaches
12%
Markov Decision Model
12%
Markov
12%
Economic Consequences
12%
Clinical Consequences
12%
Transferability
12%
Medicine and Dentistry
Infection
100%
Cost-Effectiveness Analysis
100%
Carbapenem
100%
Avibactam Plus Ceftazidime
100%
Colistimethate
62%
Health Care Cost
50%
Bloodstream Infection
50%
Enterobacteriaceae
50%
Long-Term Care
25%
Health Status
12%
Quality Adjusted Life Year
12%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Carbapenem
100%
Avibactam Plus Ceftazidime
100%
Colistimethate
62%
Enterobacteriaceae
50%
Bloodstream Infection
50%
Health Status
12%